Pharmaceutical Technology's In the Lab eNewsletter
Cellink’s BIO X6, a six-printhead bioprinting platform, offers the capability to combine more materials, cells, and tools to enhance research applications across the bioprinting field.
BIO X6, a six-printhead bioprinting platform recently launched by Cellink, a Boston, MA-based bioprinting company, enables users to combine more materials, cells, and tools than other systems on the market, offering flexibility in bioprinting. The product, launched in September 2019, incorporates the company’s patented Clean Chamber Technology and intelligent exchangeable printhead technology.
The BIO X6 can meet the needs of advanced tissue engineers, regenerative medicine labs, and cancer biologists that require high-throughput bioprinting and dispensing.
“Organs and tissues are comprised of many different cell types. With the BIO X6, users can combine six or more cell types to print advanced organ and tissue models. [It] gives the user freedom to combine multiple materials in one print, and the capability to create more complex architectures,” said Itedale Namro Redwan, chief scientific officer, Cellink, in a company press release. “Being able to use different pressures, temperatures, and printing methods simultaneously in six different positions is revolutionary. Users can mix the cells in each printhead with a tailored bioink, providing the cells with the biological environment they need to achieve the desired architecture.”
The system comes with a movable arm mount, enabling multiple possibilities in one system. Users can either control through a Wi-Fi connection or through a detachable tablet on the movable arm mount.
Source: Cellink
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.